Neurophth Bio of Wuhan raised $62 million in a B round to develop its AAV-delivered gene therapies for ocular diseases. The company plans to use the proceeds for IND submissions, a commercially scalable Suzhou GMP manufacturing facility, translational research centers and its portfolio of gene therapies for ocular diseases. Its lead drug, NR082, was granted US orphan disease designation to treat Leber hereditary optic neuropathy (LHON). The B round was led by Guofang Capital and InnoVision Capital.
For further information, see ChinaBio Today (http://www.chinabiotoday.com/articles/neurophth-62-million)